Study of E2086 for adults with narcolepsy
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have narcolepsy type 1 (with cataplexy) or type 2 (without cataplexy), diagnosed within the last 10 years
- You experience significant daytime sleepiness (Epworth Sleepiness Scale score of 10 or higher)
- You have a regular sleep schedule (bedtime between 10 p.m. and 1 a.m., wake time between 5 a.m. and 10 a.m., and spend 7 to 9 hours in bed)
- You are not taking certain medications for narcolepsy or sleep (like stimulants, sedatives, or antidepressants) and can stop them 5 half-lives before the study starts
- You do not have moderate to severe sleep apnea, unstable psychiatric conditions, or other significant medical issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.
This study tests whether a new medication called samelisant can reduce extreme daytime sleepiness and sudden muscle weakness (cataplexy) in people with narcolepsy. If it works, it could offer a new treatment option for managing this sleep disorder.
This study tests whether a new medication called Lu AH69593 is safe and well-tolerated in healthy adults and people with narcolepsy type 1. Researchers want to understand how the drug affects the body and whether it could help treat excessive daytime sleepiness.
This study is looking at how common and how severe excessive daytime sleepiness (hypersomnia) is in children and teenagers with various sleep and developmental conditions. If your child has one of these conditions and struggles with sleepiness, they may be able to join to help doctors better understand and treat it.
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
Hear when a new Narcolepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.